Vaccine Demand Spurs Innovation
Vaccine development is on a roll, boosted by biomedical research uncovering new molecular targets for preventives and treatments.
The Future of Cancer Care?
Human behavior may be the most significant variable in the future of cancer care in two sense.
The British Medical Journal's Statin 'Apology'
For any Brit involved in medical publishing, the British Medical Journal (BMJ) is the Holy Grail.
The CMO Industry: Stuck in Neutral
PharmSource recently completed an analysis of the dose CMO industry’s share of new FDA approvals.
How BMS is Doing RBM (Risk-Based Monitoring)
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Future Brighter for MNCs in Mexico, Says Report
Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma.
FDA Takes First Amendment Issues "Seriously"
Several legal cases have challenged the Food and Drug Administration’s approach to regulating industry communications about medical products.
US Pharmacopeia Head Wants Fresh Outlook
In anticipation of the 200th anniversary of the United States Pharmacopeia (USP) in 2020.
Novartis and Servier in Oncology Collaboration
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
FDA, Drug Companies Struggle with Compassionate Use Requests
A national publicity campaign recently succeeded in obtaining early access to an experimental treatment for a seriously ill child,
Eight Ingredients for a Successful Oncology Drug Development Recipe
In light of the risks and challenges inherent in the development of oncologics.
Strategic Development Partnerships: Preparing for Inevitable Challenges
It’s hardly news that biopharmaceutical companies today face increasing pressure to innovate, produce, improve efficiency and quality.
Antibiotics Discovery: Time for a ‘Manhattan Project’
The innovative pharmaceutical industry is under attack from critics around the world for failing to develop new antibiotics to treat emerging infections.
Pharm Exec's Brand of the Year Applauds the Old and the New
Pharm Exec’s Brand of the Year award is itself a brand with staying power - our first recipient was Merck’s Gardasil papillomavirus vaccine.
European Pharma Launches Strategy Manifesto
Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
Merger Mania: When the Music Stops
As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again.
Middle East Meltdown: Diabetes in the Arab Context
Diabetes, it can be said, is one of the unpleasant side-effects of being human.
Pfizer–AstraZeneca Implications for the Future of International Pharma
The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry.
England: Ignoring NICE Guidelines Can Be Unlawful
A CCG had denied funding for oocyte preservation for a woman with Crohn’s disease before she had bone marrow transplant and chemotherapy.
Go Digital From Get-Go: Boosting Patient Communication at Point of Care
In our final Q&A installment previewing next week’s iPharma2014 digital forum.
Sovaldi “Biggest Selling Drug” by 2020
Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate.
Filling the Digital Skills Gap
More than half a century ago, way before anyone had dreamt up the notion of digital disruption.
Pfizer’s AZ Bid Draws Mixed UK Reaction
The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK.
The United Kingdom: Rx for America's Pharma Tax Blues?
The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing.
New Pancreatic Cancer Drugs' Revenue Potential "Limited"
The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research.
European Pharma Must Get Its Data in Order
New data maintenance guidelines have sparked a flurry of activity in Europe.
Pursuing the 'Real' Cost Effectiveness Threshold in England
The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE).
High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment
Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market.
Medicare Data Raises Questions About Drug Costs
The recently released Medicare data on payments to individual doctors doesn’t provide specifics on prescription drug outlays,
Big Pharma’s Big Tuesday: A New Age of Megamerger?
Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK.
